EntreMed, Inc. Presents Panzem(R) NCD Phase Ib Clinical Trial Results

ROCKVILLE, Md., Nov. 16 /PRNewswire-FirstCall/ -- EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced interim results for two Phase Ib studies for its lead clinical-stage drug candidate, Panzem(R) NCD, in patients with advanced cancer. The data were presented by principal investigators, George Wilding, M.D., Director, University of Wisconsin Comprehensive Cancer Center, and Christopher J. Sweeney, M.D., Co-Director, Experimental and Developmental Therapeutics Program, Indiana University Cancer Center, during a poster session at the combined American Association for Cancer Research, National Cancer Institute, European Organization for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference on Molecular Targets and Cancer Therapeutics being held this week in Philadelphia, Pennsylvania.

(Logo: Newscom: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Results from both dose-escalation studies concluded that the pharmacokinetic profile of Panzem(R) NCD met the study objective. Specifically, a dose and schedule of administration was determined that provided constant exposure of 2-methoxyestradiol allowing the selection of a Phase II dose. Results from the University of Wisconsin have determined a maximum tolerated dose with fatigue as the dose limiting toxicity.

EntreMed also presented preclinical data in animal tumor models in which different blood levels of 2ME2 were correlated with tumor responses. Data demonstrated that significant therapeutic activity in three distinct tumor models was achieved by maintaining 2ME2 blood levels in the low ng/mL range over a 24 hour dosing period. The therapeutic activity was independent of the route of administration provided that sustained blood levels of 2ME2 were achieved. The blood concentration range of 2ME2 required for significant tumor response is approximately 100-fold lower than effective in vitro concentrations, and may be attributable to 2ME2's multiple mechanism of action, as well as its independent actions on both the tumor cell and vascular compartments of a cancer.

Carolyn F. Sidor, M.D., M.B.A., EntreMed Vice President and Chief Medical Officer, commented on the results of the studies, "We are pleased with the overall results of the Phase Ib studies. The primary objectives for these trials have been met, an optimal dose has been determined, and we have a schedule for dosing Panzem(R) NCD. In addition, 2ME2 blood concentrations that are associated with significant preclinical antitumor activity can now be sustained in cancer patients following oral administration with Panzem(R) NCD. Plans for multiple Phase II studies are currently underway."

To view the poster presentations, visit Scientific Presentations under the Therapeutic Pathways section of the Company's web site at http://www.entremed.com.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R) (2-methoxyestradiol or 2ME2), the Company's lead drug candidate, is currently in clinical trials for cancer, as well as in preclinical development for non-oncology indications. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's website at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

CONTACT: Ginny Dunn, Associate Director, Corporate Communications & Investor Relations of EntreMed, Inc., +1-240-864-2643.

Photo: Newscom: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk photodesk@prnewswire.comEntreMed, Inc.

CONTACT: Ginny Dunn, Associate Director, Corporate Communications &Investor Relations of EntreMed, Inc., +1-240-864-2643

Back to news